SEC Form 4 · accession 0001209191-18-034204

Iterum Therapeutics plc · ITRM

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Director

Period of report

May 30, 2018

Accepted (ET)

May 30, 2018 · 5:26 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001659323

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Ordinary Shares^F1,F2	May 30, 2018	C	721,408	—	A	721,408	I	By Canaan X, L.P.
Ordinary Shares^F3,F2	May 30, 2018	C	275,446	—	A	996,854	I	By Canaan X, L.P.
Ordinary Shares^F4,F2	May 30, 2018	C	229,660	—	A	1,226,514	I	By Canaan X, L.P.
Ordinary Shares^F2	May 30, 2018	P	506,656	$13.00	A	1,733,170	I	By Canaan X, L.P.

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	D/I
Series A Preferred Shares^F2,F1	—	May 30, 2018	C	721,408	D	—	—	Ordinary Shares	721,408	I
Series B-1 Preferred Shares^F2,F3	—	May 30, 2018	C	275,446	D	—	—	Ordinary Shares	275,446	I
Series B-2 Preferred Shares^F2,F4	—	May 30, 2018	C	229,660	D	—	—	Ordinary Shares	229,660	I

F1The Series A Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer and had no expiration date.
F2These shares are held directly by Canaan X L.P. (the "Canaan Fund"). The sole general partner of the Canaan Fund is Canaan Partners X LLC ("Canaan X", and together with the Canaan Fund, the "Canaan Entities"). Investment and voting decisions with respect to the shares held by the Canaan Fund are made by the managers of Canaan X, collectively. The Reporting Person, a manager and member of Canaan X, serves as the representative of the Canaan Entities on the Issuer's board of directors. The Reporting Person disclaims Section 16 beneficial ownership in the securities held by the Canaan Entities, except to the extent of his pecuniary interest therein, if any, in such securities by virtue of the limited liability company interests he owns in Canaan X.
F3The Series B-1 Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer and had no expiration date.
F4The Series B-2 Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer and had no expiration date.